Spots Global Cancer Trial Database for denileukin diftitox
Every month we try and update this database with for denileukin diftitox cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Trial of Ontak With Metastatic Melanoma | NCT00299689 | Malignant Melan... | Denileukin dift... | 18 Years - | James Graham Brown Cancer Center | |
| A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer | NCT00726037 | Metastatic Panc... | Ontak | 18 Years - | Loyola University | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00026429 | Leukemia Lymphoma | denileukin dift... | 18 Years - | National Cancer Institute (NCI) | |
| Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak) | NCT01432483 | Cancer | Denileukin dift... | - | Eisai Inc. | |
| Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma | NCT01127451 | Stage IIIC Mela... Stage IV Melano... | Denileukin dift... | 18 Years - | Eisai Inc. | |
| Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia | NCT00082940 | Leukemia | denileukin dift... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak) | NCT01432483 | Cancer | Denileukin dift... | - | Eisai Inc. | |
| Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia | NCT00082940 | Leukemia | denileukin dift... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | NCT00945269 | Recurrent Melan... Stage III Melan... Stage IV Melano... | therapeutic aut... aldesleukin denileukin dift... biopsy immunohistochem... laboratory biom... polymerase chai... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00026429 | Leukemia Lymphoma | denileukin dift... | 18 Years - | National Cancer Institute (NCI) | |
| Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine | NCT00228358 | HER2-positive B... Recurrent Breas... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Stage IV Breast... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... | ex vivo-expande... cyclophosphamid... denileukin dift... flow cytometry immunoenzyme te... | 18 Years - | University of Washington | |
| Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | NCT00493129 | Leukemia Systemic Mastoc... | Ontak (Denileuk... | - | M.D. Anderson Cancer Center | |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | NCT00945269 | Recurrent Melan... Stage III Melan... Stage IV Melano... | therapeutic aut... aldesleukin denileukin dift... biopsy immunohistochem... laboratory biom... polymerase chai... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer | NCT00357448 | Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Mixed E... Ovarian Mucinou... Ovarian Serous ... Ovarian Undiffe... Peritoneal Cavi... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | denileukin dift... intraperitoneal... laboratory biom... enzyme-linked i... flow cytometry | 18 Years - | University of Washington | |
| Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma | NCT00460109 | Lymphoma | denileukin dift... rituximab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00026429 | Leukemia Lymphoma | denileukin dift... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma | NCT00211185 | Lymphoma, T-Cel... | Denileukin dift... Cyclophosphamid... Doxorubicin Vincristine Prednisone Pegfilgrastim | 18 Years - | Eisai Inc. | |
| Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML) | NCT01106950 | Leukemia, Myelo... | Natural Killer ... Fludarabine Cyclophosphamid... Denileukin dift... Donor lymphaphe... IL-2 | 2 Years - | Masonic Cancer Center, University of Minnesota | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00003615 | Lymphoma | denileukin dift... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) | NCT00632827 | Peripheral T-Ce... | Gemcitabine Navelbine Doxorubicin Hyd... Granulocyte-col... Pegfilgrastim Cyclophosphamid... Vincristine Leucovorin Methotrexate Doxorubicin Hyd... Cytarabine Etoposide Carmustine Denileukin dift... | 18 Years - 70 Years | University of California, San Francisco | |
| Denileukine Diftitox for Relapsed ALCL | NCT00801918 | Anaplastic Larg... | Denileukin Dift... Denileukin dift... | 2 Years - 24 Years | Columbia University | |
| Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia | NCT00082940 | Leukemia | denileukin dift... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Phase II Trial of Ontak With Metastatic Melanoma | NCT00299689 | Malignant Melan... | Denileukin dift... | 18 Years - | James Graham Brown Cancer Center | |
| A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma | NCT00211185 | Lymphoma, T-Cel... | Denileukin dift... Cyclophosphamid... Doxorubicin Vincristine Prednisone Pegfilgrastim | 18 Years - | Eisai Inc. | |
| Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | NCT00493129 | Leukemia Systemic Mastoc... | Ontak (Denileuk... | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
